Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares shot up 4.5% during mid-day trading on Thursday . The company traded as high as $7.06 and last traded at $7.00, with a volume of 61,482 shares changing hands. The stock had previously closed at $6.70.

A number of brokerages have recently issued reports on KPTI. Leerink Swann reiterated a “buy” rating and issued a $18.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, May 10th. Jefferies Group downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price target on the stock. in a report on Wednesday, June 1st. Wedbush reiterated an “outperform” rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, August 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 21st. Finally, Raymond James Financial Inc. initiated coverage on Karyopharm Therapeutics in a report on Friday, May 27th. They issued an “outperform” rating and a $13.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $17.45.

The stock’s market cap is $250.84 million. The firm’s 50 day moving average is $7.13 and its 200-day moving average is $7.78.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. Analysts forecast that Karyopharm Therapeutics Inc. will post ($3.27) earnings per share for the current year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 18,824 shares of the company’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC boosted its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent reporting period.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.